India, Nov. 6 -- The Government of India has issued a release:

Affordable, quality cancer care for every family is a priority for the Government of India. On October 17, 2026, the National Pharmaceutical Pricing Authority (NPPA) capped the trade margin on 137 non-scheduled anti-cancer medicines, including patented ones, at 30% of the maximum retail price (MRP). The revised prices take effect on November 9, 2026. By November 4, 2026, 70 companies had reported revised MRPs for 120 drugs, with the highest reduction at 96.45% and estimated savings of Rs. 3,357.49 crore. MRP reductions average 20% to 70%.

Cancer Medicine Prices Reduced by 20% to 70% on Average

What Is a Trade Margin?

Trade margin is the difference between the price a manufacturer charges a stockist/distributor and the highest price (MRP) a patient pays for a medicine excluding Goods and Services Tax (GST). When this trade margin is very high, large profits are added along the supply chain. This heavily inflates the final cost for patients, making already expensive cancer drugs far more costly than the price at which the manufacturer sells them.

How Medicine Prices Are Regulated

What Is the National List of Essential Medicines?

The National List of Essential Medicines (NLEM) is an official list of necessary, high-priority medicines for India. Its latest revision, NLEM 2022, was released by Union Health Minister Dr. Mansukh Mandaviya on September 13, 2022, under the Government's vision of "Sabko Dawai, Sasti Dawai" (Medicine for everyone, affordable medicine).

How the New Order Limits Trade Margins on Cancer Medicines

Sr. No.

Name of the Drug

Sr. No.

Name of the Drug

1

Abemaciclib

70

Lenvatinib

2

Abiraterone acetate

71

Lomustine

3

Acalabrutinib

72

Lorlatinib

4

Afatinib

73

Lymphoseek kit

5

Alectinib

74

Megestrol

6

Alpelisib

75

Midostrurin

7

Amivantamab

76

Mirvetuximab soravtansine

8

Anastrazole

77

Mitomycin

9

Apalutamide

78

Mitoxantrone

10

Asciminib

79

Nelarabine

11

Atezolizumab

80

Netupitant

12

Avelumab

81

Nilotinib

13

Axitinib

82

Nimotuzumab

14

Azacitidine

83

Nintedanib

15

Belantamab Mafodotin

84

Niraparib

16

Bevacizumab

85

Nivolumab

17

Bosutinib

86

Obinutuzumab

18

Brentuximab Vedotin

87

Ofatumumab

19

Brigatinib

88

Olaparib

20

Busulfan

89

Osimertinib

21

Cabazitaxel

90

Palbociclib

22

Cabozantinib (S)- Maleate

91

Panitumumab (Vectibix)

23

Capmatinib

92

Pazopanib (as Hydrochloride)

24

Carfilzomib

93

Pegasparginase

25

Carmustine

94

Pegfilgrastim

26

Ceritinib

95

Pegylated interferon Alpha 2B

27

Cetuximab

96

Pembrolizumab

28

Cladribine

97

Pemetrexed

29

Clofarabine

98

Pertuzumab

30

Crizotinib

99

Pertuzumab + Trastuzumab

31

Cytarabine

100

Plerixafor

32

Dabrafenib

101

Polatuzumab Vedotin

33

Dacomitinib

102

Pomalidomide

34

Daratumumab

103

Ramucirumab

35

Darolutamide

104

Regorafenib

36

Dasatinib

105

Relugolix

37

Datopotamab Deruxtecan

106

Ribociclib

38

Decitabine

107

Rucaparib

39

Degarelix

108

Ruxolitinib

40

Denosumab

109

Selpercatinib

41

Dostarlimab

110

Selumetinib

42

Durvalumab

111

Serplulimab

43

Elranatamab

112

Sotorasib

44

Enfortumab vedotin

113

Sunitinib

45

Entrectinib

114

Talquetamab

46

Enzalutamide

115

Teclistamab

47

Epirubicin

116

Tegafur + Uracil

48

Erdafitinib

117

Tegafur, Gimeracil and Oteracil

49

Eribulin mesylate

118

Temsirolimus

50

Erlotinib

119

Tepotinibe

51

Estramustine

120

Thiotepa

52

Everolimus

121

Tislelizumab

53

Exemestane

122

Tocilizumab

54

Fludarabine

123

Topotecan

55

Fulvestrant

124

Toripalimab

56

Gilteritinib

125

Trabectedin

57

Goserelin acetate

126

Trametinib

58

Ibritumomab

127

Tremelimumab

59

Ibrutinib

128

Treosulfan

60

Idelalisib

129

Trifluridine + Tipiracil

61

Ifosfamide & Mesna

130

Triptorelin

62

Nivolumab and Relatimab

131

Tucatinib

63

Pegylated Liposomal Irinotecan

132

Vemurafenib

64

Inotuzumab Ozogamicin

133

Venetoclax

65

Interferon Alpha 2B

134

Vinorelbine tartrate

66

Ipilimumab

135

Vorasidenib

67

Ivosidenib

136

Zanubrutinib

68

Lapatanib

137

Zolbetuximab

69

Lazertinib

Wider Government Support for Cancer Care

Making Cancer Treatments Affordable and Accessible

History: First created in 1996, then updated in 2003, 2011, 2015, and 2022.

Who Made It: An expert panel called the Standing National Committee on Medicines (SNCM), after talking with doctors, scientists, industry experts, and checking WHO standards.

Why the List Matters

The Legal Power Behind the Order: Paragraph 19 of the DPCO, 2013

The Government has capped excessive markups along the pharmaceutical supply chain, in retail and hospital pharmacies across the country, to make cancer treatment in India more affordable.

The Order sets the new maximum retail price of each medicine from its average distributor price of March 2026. The trade margin within that price can be no more than 30%, and GST is added on top.

How the New Maximum Retail Price (MRP) Is Calculated

The Order sets the formula for the maximum retail price a patient can be charged:

Anti-Cancer Medicines Covered by the Order

Source: Ministry of Chemicals and Fertilizers, NPPA Order S.O. 5690(E) of October 17, 2026

What Changes for Patients and Companies

The Government runs various health programmes to provide affordable cancer care treatment, screenings and medicines for the public.

AB-PMJAY: Cashless Hospital Care, Including Cancer Treatment

NP-NCD: Cancer Care from Screening to Treatment

Screening for Common Cancers at Primary Healthcare Centres

Free HPV Vaccination to Prevent Cervical Cancer

Low-Cost Medicine Outlets: Jan Aushadhi and AMRIT

Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)

Affordable Medicines and Reliable Implants for Treatment Pharmacies

Teleconsultations for Cancer Care

Teleconsultation services are provided through the eSanjeevani platform to improve access to specialist care, particularly in remote and underserved areas. This includes oncology care.

The trade margin cap adds to the support the Government already gives at every stage of cancer care: screening at Ayushman Arogya Mandirs, free HPV vaccination for girls, cashless hospital treatment under AB-PMJAY, and lower-cost medicines at Jan Aushadhi Kendras and AMRIT pharmacies. Together, these measures bring quality cancer care within reach of more families, closer to where they live.

References

Ministry of Chemicals and Fertilizers

https://www.pib.gov.in/PressReleasePage.aspx?PRID2321092®48&lang2

https://www.pib.gov.in/PressReleasePage.aspx?PRID2324743

https://nppa.gov.in/storage/uploads/tender/277271-17-10-2026.pdf

https://www.pib.gov.in/PressReleasePage.aspx?PRID2297568®3&lang1

https://nppa.gov.in/storage/uploads/pdf/DPCO-inclusive-of-all-ammendmentscompressedpdf-6f9edc1bf7c000eb02b7eee6c180b527.pdf

https://nppa.gov.in/en/search_medicine_price

https://www.pib.gov.in/PressReleasePage.aspx?PRID2329698

https://nppa.gov.in/storage/uploads/tender/revised-mrp-report-04112026-04-11-2026.pdf

https://x.com/nppa_india/status/2117986916121628974

https://x.com/Pharmadept/status/2117305360692466164

Ministry of Health and Family Welfare

https://www.pib.gov.in/PressReleasePage.aspx?PRID1858931®48&lang2

https://www.pib.gov.in/PressReleasePage.aspx?PRID2286948®48&lang2

https://www.pib.gov.in/PressReleasePage.aspx?PRID2294278

https://dashboard.nha.gov.in/public/

https://sansad.in/getFile/lsapps/loksabhaquestions/annex/188/AU931_DhFQWt.pdf

https://elibrary.sansad.in/server/api/core/bitstreams/b3b40e24-2357-43ce-b2ec-89a9d548f521/view

https://www.pib.gov.in/PressReleaseDetail.aspx?PRID2309109®3&lang1

https://esanjeevani.mohfw.gov.in/

https://www.pib.gov.in/PressReleasePage.aspx?PRID2314433®48&lang2

PIB Backgrounders

https://www.pib.gov.in/FactsheetDetails.aspx?Id150834®5&lang1

Click to see pdf

Disclaimer: Curated by HT Syndication.